2021 Fiscal Year Final Research Report
Identification of anti-neuronal autoantibody in patients with idiopathic cerebellar ataxia
| Project/Area Number |
19K17029
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 自己抗体 / 小脳性運動失調症 / 自己免疫性小脳性運動失調症 / 自己免疫性脳炎 |
|---|
| Outline of Final Research Achievements |
The key questions for this research project are: 1) How many IDCA patients have an immunological background? 2) What is the role of antibodies in the pathogenesis? 3)What are the clinical characteristics of antibody-positive IDCA patients? Our study revealed that anti-cerebellar antibodies are detected in about 30% of patients with IDCA and about 10% of patients with multiple system atrophy, and that some of these antibodies may be related to the pathophysiology of the disease, since they are clearly more frequently detected in IDCA. Patients with IDCA who tested positive for antibodies were significantly more likely to have cerebellar hypoperfusion than those who tested negative for antibodies.
|
| Free Research Field |
神経免疫疾患
|
| Academic Significance and Societal Importance of the Research Achievements |
我々の研究によって，これまで主に変性疾患と考えられてきた特発性小脳失調症IDCAにおいて，免疫病態が関与している患者が非常に高率に存在していることが示された．このことはIDCA患者における，治療可能な集団を見出すことにもつながると考えられた．そのため，本研究の結果を元にした，抗小脳抗体陽性のIDCA患者における，免疫療法の有効性を検討するための臨床試験を行うことが必要と考え，我々は，「特発性小脳失調症に対する免疫療法の有効性および安全性を検証するランダム化並行群間試験」を計画し，実行することにした．現在，この医師主導治験が進行中である．
|
